$500 Million is the total value of Logos Global Management LP's 46 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 143.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FMTX | New | FORMA THERAPEUTICS HLDGS INC | $59,507,000 | – | 1,280,000 | +100.0% | 11.89% | – |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $31,204,000 | +162.7% | 200,000 | +143.0% | 6.24% | +38.0% |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $26,000,000 | – | 2,000,000 | +100.0% | 5.20% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $25,556,000 | – | 926,454 | +100.0% | 5.11% | – |
| RPTX | New | REPARE THERAPEUTICS INC | $20,293,000 | – | 666,894 | +100.0% | 4.06% | – |
| BNTX | New | BIONTECH SEsponsored ads | $19,688,000 | – | 295,000 | +100.0% | 3.93% | – |
| CYTK | Buy | CYTOKINETICS INC | $18,856,000 | +728.1% | 800,000 | +314.2% | 3.77% | +335.1% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $16,902,000 | – | 268,500 | +100.0% | 3.38% | – |
| AMTI | New | APPLIED MOLECULAR TRANS INC | $16,698,000 | – | 664,186 | +100.0% | 3.34% | – |
| TGTX | Buy | TG THERAPEUTICS INC | $16,558,000 | +573.6% | 850,000 | +240.2% | 3.31% | +253.9% |
| AKBA | New | AKEBIA THERAPEUTICS INC | $16,296,000 | – | 1,200,000 | +100.0% | 3.26% | – |
| BTAI | New | BIOXCEL THERAPEUTICS INC | $15,903,000 | – | 300,000 | +100.0% | 3.18% | – |
| IMVT | New | IMMUNOVANT INC | $15,219,000 | – | 625,000 | +100.0% | 3.04% | – |
| KROS | New | KEROS THERAPEUTICS INC | $15,004,000 | – | 400,000 | +100.0% | 3.00% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $14,568,000 | – | 456,426 | +100.0% | 2.91% | – |
| PCVX | New | VAXCYTE INC | $14,383,000 | – | 455,000 | +100.0% | 2.87% | – |
| BMYRT | Buy | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $14,320,000 | +195.4% | 4,000,000 | +213.6% | 2.86% | +55.2% |
| ZGNX | Buy | ZOGENIX INC | $10,804,000 | +187.1% | 400,000 | +162.9% | 2.16% | +50.9% |
| AKUS | New | AKOUOS INC | $10,125,000 | – | 450,000 | +100.0% | 2.02% | – |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $8,969,000 | – | 150,000 | +100.0% | 1.79% | – |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $8,523,000 | -10.3% | 135,000 | -27.4% | 1.70% | -52.9% |
| PASG | Sell | PASSAGE BIO INC | $8,472,000 | -5.4% | 344,438 | -42.9% | 1.69% | -50.3% |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $7,499,000 | +17.9% | 410,000 | -23.0% | 1.50% | -38.0% |
| CALT | New | CALLIDITAS THERAPEUTICS ABsponsered ads | $6,990,000 | – | 300,000 | +100.0% | 1.40% | – |
| OBSV | New | OBSEVA SA | $6,862,000 | – | 1,165,000 | +100.0% | 1.37% | – |
| GBIO | New | GENERATION BIO CO | $6,825,000 | – | 325,000 | +100.0% | 1.36% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $6,811,000 | – | 562,900 | +100.0% | 1.36% | – |
| IGMS | Sell | IGM BIOSCIENCES INC | $6,704,000 | -31.3% | 91,841 | -47.2% | 1.34% | -63.9% |
| BLU | Sell | BELLUS HEALTH INC NEW | $6,174,000 | -20.2% | 600,000 | -22.6% | 1.23% | -58.1% |
| ETNB | Buy | 89BIO INC | $5,780,000 | -7.3% | 290,000 | +17.4% | 1.16% | -51.3% |
| New | APTOSE BIOSCIENCES INC | $4,733,000 | – | 750,000 | +100.0% | 0.95% | – | |
| BDTX | BLACK DIAMOND THERAPEUTICS I | $4,685,000 | +69.0% | 123,465 | 0.0% | 0.94% | -11.2% | |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $4,620,000 | – | 110,000 | +100.0% | 0.92% | – |
| ISEE | New | IVERIC BIO INC | $4,590,000 | – | 900,000 | +100.0% | 0.92% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $4,498,000 | – | 155,000 | +100.0% | 0.90% | – |
| LSACU | LIFESCI ACQUISITION CORPunit 03/31/2025 | $4,400,000 | +10.0% | 400,000 | 0.0% | 0.88% | -42.2% | |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $3,140,000 | +1320.8% | 150,000 | +848.8% | 0.63% | +646.4% |
| STRO | New | SUTRO BIOPHARMA INC | $2,809,000 | – | 361,945 | +100.0% | 0.56% | – |
| FUSN | New | FUSION PHARMACEUTICALS INC | $2,116,000 | – | 121,128 | +100.0% | 0.42% | – |
| CHAQU | New | CHARDAN HEALTHCR ACQSTN 2 COunit 99/99/9999 | $2,100,000 | – | 200,000 | +100.0% | 0.42% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $1,477,000 | – | 158,484 | +100.0% | 0.30% | – |
| ARYBU | New | ARYA SCIENCES ACQUISTION COunit 06/09/2027 | $1,160,000 | – | 100,000 | +100.0% | 0.23% | – |
| LUMO | New | LUMOS PHARMA INC | $825,000 | – | 50,000 | +100.0% | 0.16% | – |
| LRMR | New | LARIMAR THERAPEUTICS INC | $739,000 | – | 57,475 | +100.0% | 0.15% | – |
| MREO | New | MEREO BIOPHARMA GROUP PLCads | $612,000 | – | 200,000 | +100.0% | 0.12% | – |
| APLT | New | APPLIED THERAPEUTICS INC | $455,000 | – | 12,600 | +100.0% | 0.09% | – |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -53,034 | -100.0% | -0.44% | – |
| SVRA | Exit | SAVARA INC | $0 | – | -613,999 | -100.0% | -0.45% | – |
| NERV | Exit | MINERVA NEUROSCIENCES INC | $0 | – | -309,745 | -100.0% | -0.71% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -69,591 | -100.0% | -0.76% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INCcall | $0 | – | -33,300 | -100.0% | -0.97% | – |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -1,111,867 | -100.0% | -1.02% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -46,399 | -100.0% | -1.36% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -276,635 | -100.0% | -1.42% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -995,600 | -100.0% | -1.53% | – | |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -446,882 | -100.0% | -1.57% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -193,144 | -100.0% | -1.63% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -39,644 | -100.0% | -1.64% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -75,000 | -100.0% | -1.67% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -105,512 | -100.0% | -1.70% | – |
| TXG | Exit | 10X GENOMICS INC | $0 | – | -72,831 | -100.0% | -1.73% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -69,658 | -100.0% | -1.91% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -2,325,582 | -100.0% | -2.10% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -438,831 | -100.0% | -2.22% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -247,248 | -100.0% | -2.82% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -33,237 | -100.0% | -3.01% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -304,417 | -100.0% | -4.11% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -194,500 | -100.0% | -4.12% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -120,000 | -100.0% | -5.14% | – |
| MRNA | Exit | MODERNA INC | $0 | – | -460,000 | -100.0% | -5.24% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -300,000 | -100.0% | -5.35% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -187,350 | -100.0% | -6.97% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -265,600 | -100.0% | -7.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.